Pfizer Inc Stock Debt To Equity
| PFE Stock | EUR 24.57 0.13 0.53% |
Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.
Pfizer |
Pfizer Inc Company Debt To Equity Analysis
Pfizer's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Pfizer Debt To Equity | 78.80 % |
Most of Pfizer's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Pfizer Inc has a Debt To Equity of 78%. This is 47.18% higher than that of the Healthcare sector and 27.96% lower than that of the Drug Manufacturers - Major industry. The debt to equity for all Germany stocks is 61.81% lower than that of the firm.
Pfizer Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in debt to equity category among its peers.
Pfizer Fundamentals
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 2.85 X | |||
| Revenue | 100.33 B | |||
| Gross Profit | 66.23 B | |||
| EBITDA | 39.58 B | |||
| Net Income | 31.37 B | |||
| Cash And Equivalents | 11.7 B | |||
| Cash Per Share | 2.10 X | |||
| Total Debt | 34.76 B | |||
| Debt To Equity | 78.80 % | |||
| Current Ratio | 1.54 X | |||
| Book Value Per Share | 17.03 X | |||
| Cash Flow From Operations | 32.58 B | |||
| Earnings Per Share | 5.16 X | |||
| Price To Earnings To Growth | 1.19 X | |||
| Number Of Employees | 83 K | |||
| Beta | 0.58 | |||
| Market Capitalization | 212.98 B | |||
| Total Asset | 181.48 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.17 % | |||
| Net Asset | 181.48 B | |||
| Last Dividend Paid | 1.6 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.